Eli Lilly announced a $6.3 billion cash acquisition of Centessa Pharmaceuticals plc, valuing the company at $38.00 per share. The deal includes a non‑transferable contingent value right that could pay up to $9.00 per share if Centessa’s orexin‑agonist candidates receive FDA approval for narcolepsy type 2, idiopathic hypersomnia, or any indication before January 1, 2030. The contingent value right is structured as $2 per share for FDA approval of cleminorexton (ORX750) or ORX142 for narcolepsy type 2 within five years of closing, $5 per share for approval in idiopathic hypersomnia within five years, and $2 per share for the first FDA approval in any indication before the 2030 deadline. The transaction values Centessa at roughly $6.3 billion upfront and up to $7.8 billion including milestone payments, and is expected to close in the third quarter of 2026 pending regulatory and shareholder approvals.
The acquisition strengthens Lilly’s neuroscience platform, adding Centessa’s orexin receptor 2 (OX2R) agonist pipeline to a portfolio that has historically focused on incretin‑based drugs for obesity and diabetes. Centessa’s lead candidate, cleminorexton, has shown promise in Phase IIa studies for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, positioning Lilly to compete directly with other orexin agonist developers such as Takeda’s oveporexton and Alkermes’ alixorexton. Lilly’s prior M&A activity, including the 2019 $8 billion acquisition of Loxo Oncology, demonstrates a broader strategy to diversify beyond its core products and accelerate growth in high‑potential therapeutic areas.
Centessa’s financials underscore the strategic value of the deal. The company reported a net loss of $54.9 million in Q3 2025 and a cumulative net loss of $235.76 million over the last four quarters, reflecting significant burn and limited capital runway. The $38.00 per share offer represents a 40.5% premium to the 30‑day volume‑weighted average trading price of $27.58 on March 30, 2026, providing immediate liquidity and removing the capital‑runway constraints that have limited Centessa’s ability to advance its pipeline.
Carole Ho, Executive Vice President and President of Lilly Neuroscience, said, "Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience as a direct intervention on the master switch of the sleep‑wake cycle. Centessa has assembled a portfolio with the breadth and depth to improve wakefulness across a broad array of indications. Joining forces with Centessa colleagues means we can now pursue that potential at the speed and scale it deserves." Mario Alberto Accardi, PhD, CEO of Centessa, added, "Centessa is at the forefront of orexin science, and we've built a potential best‑in‑class portfolio of OX2R agonists with a level of depth and breadth that could help redefine what's possible in neuroscience. Driven by a bold vision, our team has advanced an innovative portfolio with the speed, rigor and conviction needed to lead a new era of orexin‑based therapeutics. Now, we are thrilled to take our next step toward a potential combination with Lilly." Accardi also noted, "This milestone reflects not only the strength of our science, but also the transformative potential of our orexin portfolio for patients who urgently need new solutions."
The market reacted positively to the announcement, driven by the substantial premium offered and the strategic fit of Centessa’s orexin‑agonist pipeline within Lilly’s expanding neuroscience portfolio. The deal is expected to enhance Lilly’s competitive position against other orexin developers and accelerate the commercialization of a potentially best‑in‑class therapy for sleep‑wake disorders.
The acquisition provides Centessa with immediate liquidity and access to Lilly’s global neuroscience platform, while positioning Lilly to accelerate development and commercialization of orexin‑agonist therapies. For investors, the deal signals Lilly’s continued commitment to diversifying its product pipeline and strengthening its foothold in high‑growth neuroscience markets. The transaction also removes Centessa’s capital‑runway constraints, enabling the company to focus on advancing its pipeline without the pressure of limited cash reserves.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.